Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial

P. Calverley (Liverpool, United Kingdom), C. Jenkins (Sydney, Australia), J. Wedzicha (London, United Kingdom), A. De La Hoz (Ingelheim am Rhein, Germany), F. Voß (Ingelheim am Rhein, Germany), K. Rabe (Grosshansdorf, Germany), A. Anzueto (San Antonio, United States of America)

Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Session: Eosinophils and FeNO in airway diseases
Session type: Oral Presentation
Number: 2149
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Calverley (Liverpool, United Kingdom), C. Jenkins (Sydney, Australia), J. Wedzicha (London, United Kingdom), A. De La Hoz (Ingelheim am Rhein, Germany), F. Voß (Ingelheim am Rhein, Germany), K. Rabe (Grosshansdorf, Germany), A. Anzueto (San Antonio, United States of America). Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. 2149

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Relationship of blood eosinophil count to exacerbations in COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016


Association between blood eosinophil count and risk of exacerbations in patients with COPD
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017


Variability in eosinophil levels at start of severe exacerbations of COPD
Source: Virtual Congress 2020 – Diagnosis and management of COPD
Year: 2020


The impact of high eosinophil count on hospitalizations in COPD patients
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018

Blood eosinophil count and exacerbation risk in patients with COPD
Source: Eur Respir J, 50 (1) 1700761; 10.1183/13993003.00761-2017
Year: 2017



Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study
Source: ERJ Open Res, 4 (3) 00022-2018; 10.1183/23120541.00022-2018
Year: 2018



CRP as predictor as predictor for late treatment failure in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013

LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015


Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis
Source: International Congress 2015 – Epidemiological studies of asthma and allergy
Year: 2015


Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker
Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Year: 2019




Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014


An evaluation of exacerbations in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 89s
Year: 2004

The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016

Eosinophil count on admission is not a good biomarker in severe exacerbations of COPD to predic later readmission: a long term observational study from the AECOPD-Barcelona Cohort
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018

Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015

Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Blood eosinophil count as a predictor of obstructive airway disease (OAD) in a high parasite burden setting
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016


COPD exacerbations and predictors in a general population
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016

Eosinophilia as marker of outcome in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD and infections
Year: 2013